基于多源生物医学数据的儿童肝胆疾病智能诊断及预后预测研究

注册号:

Registration number:

ChiCTR2500111075 

最近更新日期:

Date of Last Refreshed on:

2025-10-24 15:40:14 

注册时间:

Date of Registration:

2025-10-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于多源生物医学数据的儿童肝胆疾病智能诊断及预后预测研究

Public title:

Intelligent Diagnosis and Prognosis Prediction for Pediatric Hepatobiliary Diseases Using Multi-Source Biomedical Data

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于多源生物医学数据的儿童肝胆疾病智能诊断及预后预测研究

Scientific title:

Intelligent Diagnosis and Prognosis Prediction for Pediatric Hepatobiliary Diseases Using Multi-Source Biomedical Data

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘淑仪 

研究负责人:

刘淑仪 

Applicant:

Shuyi Liu 

Study leader:

Shuyi Liu 

申请注册联系人电话:

Applicant telephone:

+86 135 6018 5634

研究负责人电话:

Study leader's
telephone:

+86 135 6018 5634

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lsyjnu@163.com

研究负责人电子邮件:

Study leader's E-mail:

lsyjnu@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广西柳州市鱼峰区博园大道50号

研究负责人通讯地址:

广西柳州市鱼峰区博园大道50号

Applicant address:

No. 50 Boyuan Avenue, Yufeng District, Liuzhou City, Guangxi

Study leader's address:

No. 50 Boyuan Avenue, Yufeng District, Liuzhou City, Guangxi

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州市妇女儿童医疗中心柳州医院

Applicant's institution:

Guangzhou Women and Children Medical Center Liuzhou Hospital

研究负责人所在单位:

广州市妇女儿童医疗中心柳州医院

Affiliation of the Leader:

Guangzhou Women and Children Medical Center Liuzhou Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

快审-科研-2025-204

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广州市妇女儿童医疗中心柳州医院医学研究伦理委员会

Name of the ethic committee:

Ethics Committee of Guangzhou Women and Children Medical Center Liuzhou Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-09-30 00:00:00

伦理委员会联系人:

李沭

Contact Name of the ethic committee:

Shu Li

伦理委员会联系地址:

广西柳州市鱼峰区博园大道50号

Contact Address of the ethic committee:

No. 50 Boyuan Avenue, Yufeng District, Liuzhou City, Guangxi

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 177 7723 0236

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广州市妇女儿童医疗中心柳州医院

Primary sponsor:

Guangzhou Women and Children Medical Center Liuzhou Hospital

研究实施负责(组长)单位地址:

广西柳州市鱼峰区博园大道50号

Primary sponsor's address:

No. 50 Boyuan Avenue, Yufeng District, Liuzhou City, Guangxi

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广西壮族自治区

市(区县):

柳州市

Country:

China

Province:

Guangxi Zhuang Autonomous Region

City:

Liuzhou

单位(医院):

广州市妇女儿童医疗中心柳州医院

具体地址:

广西柳州市鱼峰区博园大道50号

Institution
hospital:

Guangzhou Women and Children Medical Center Liuzhou Hospital

Address:

No. 50 Boyuan Avenue, Yufeng District, Liuzhou City, Guangxi

经费或物资来源:

广州市妇女儿童医疗中心柳州医院

Source(s) of funding:

Guangzhou Women and Children Medical Center Liuzhou Hospital

研究疾病:

儿童肝病/胆汁淤积症/胆道闭锁/肝炎/肝纤维化/肝硬化/肝脏肿瘤  

Target disease:

Pediatric Liver Disease/Cholestasis/Biliary Atresia/Hepatitis/Liver Fibrosis/Liver Cirrhosis/Liver Tumors

研究疾病代码:

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

诊断试验诊断准确性 

Study design:

Diagnostic test for accuracy 

研究目的:

(1)建立儿童肝胆疾病的 MRI影像组学特征库;(2)开发人工智能多组学辅助诊断及预后预测系统。  

Objectives of Study:

(1) Creating an MRI radiomics feature repository for pediatric hepatobiliary conditions; and (2) Building an AI-driven multi-omics system for assisted diagnosis and outcome prediction.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

诊断不明确患儿

Exclusion criteria:

Patients without a definitive diagnosis

研究实施时间:

Study execute time:

From 2025-10-27 00:00:00 To 2028-10-26 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-10-27 00:00:00 To 2028-10-26 00:00:00

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

病理穿刺或病理活检

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Needle biopsy or pathological biopsy

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

影像-临床融合人工智能模型

Index test:

Image-Clinic Integrated AI Model

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

儿童肝病、胆汁淤积症、胆道闭锁、肝炎、肝纤维化、肝硬化、肝脏肿瘤

例数:

Sample size:

200

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Pediatric Liver Disease/Cholestasis/Biliary Atresia/Hepatitis/Liver Fibrosis/Liver Cirrhosis/Liver Tumors

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

神经母细胞瘤

例数:

Sample size:

100

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

Neuroblastoma

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广西壮族自治区  

市(区县):

柳州市 

Country:

China

Province:

Guangxi Zhuang Autonomous Region

City:

Liuzhou

单位(医院):

广州市妇女儿童医疗中心柳州医院 

单位级别:

三甲 

Institution
hospital:

Guangzhou Women and Children Medical Center Liuzhou Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肝纤维化分级

指标类型:

主要指标

Outcome:

Liver Fibrosis Staging

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

一致性指数

指标类型:

主要指标

Outcome:

Concordance index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

曲线下面积

指标类型:

主要指标

Outcome:

Area Under the Curve

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

准确性

指标类型:

次要指标

Outcome:

Accuracy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

敏感度

指标类型:

次要指标

Outcome:

Sensitivity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

特异度

指标类型:

次要指标

Outcome:

Specificity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

合并疾病

指标类型:

附加指标

Outcome:

Comorbidity

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

病理类型

指标类型:

附加指标

Outcome:

Histological Type

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生存时间

指标类型:

附加指标

Outcome:

Overall Survival

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 18 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-10-24 15:39:57